Roche's Lunsumio combination meets primary endpoint in late-stage blood cancer trial

Roche announced positive late-stage results for Lunsumio in combination therapy for blood cancer, showing clinically relevant efficacy. Specific data and regulatory implications remain undisclosed. This strengthens Roche's oncology pipeline and may influence future treatment standards.